Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
Solid Biosciences received European Commission Orphan designation for SGT-212, its gene therapy for Friedreich's ataxia, granting incentives including reduced fees and 10 years of EU market exclusivity if approved. The company also said five participants have been dosed in the Phase 1b FALCON trial with no treatment-related serious adverse events as of October 5, 2026.
Key figures
- Drug Name
- SGT-212
- Phase Of Trial
- Phase 1b
- Fa patients us
- 5000
- Fa patients global
- 25000
- Participants dosed
- 5
- Initial data timing
- Q1 2027
- Treatment related saes
- 0
- Eu market exclusivity years
- 10
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.